[A case of hepatocellular carcinoma with portal vein thrombus(Vp3)and lung metastases(stage IVB),which responded completely to treatment with Tegafur/Uracil].
A 65-year-old woman who had diffuse hepatocellular carcinoma(HCC)with tumor thrombus of right portalvein(Vp3) and lung metastases(Stage IVB)was treated by single-agent therapy with tegafur/uracil(UFT). As a result, primary and metastatic tumors were not recognized by diagnostic imaging, with a noted decrease of AFP, AFP-L3 and PIVKA-II. Generally, oral chemotherapy for HCC is not recommended because of the low response rate. However, there have been some reports including the present case which have showed a marked response with UFT. We thus conclude that UFT can be an option with low risk of crucial adverse effects in the treatment of selected HCC patients.
Miyano
Masato
M
Department of Gastroenterology, Osaka City Juso Hospital.
Kurai
Osamu
O
Hiramatsu
Shinsuke
S
Yamasaki
Tomoaki
T
Sasaki
Eiji
E
Adachi
Kenji
K
Oka
Hiroko
H
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000556:secondary; D009367:Neoplasm Staging; D011169:Portal Vein / Q000473:pathology; D012074:Remission Induction; D005641:Tegafur / Q000008:administration & dosage / Q000627:therapeutic use*; D013927:Thrombosis / Q000209:etiology* / Q000473:pathology; D014057:Tomography, X-Ray Computed; D014498:Uracil / Q000008:administration & dosage / Q000627:therapeutic use*
D005641:Tegafur; D014498:Uracil